vs
Side-by-side financial comparison of EyePoint, Inc. (EYPT) and Prenetics Global Ltd (PRE). Click either name above to swap in a different company.
Prenetics Global Ltd is the larger business by last-quarter revenue ($4.3M vs $619.0K, roughly 6.9× EyePoint, Inc.).
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
Prenetics (NASDAQ:PRE) is a health sciences company headquartered in Hong Kong, with a presence in the United States. It focuses on early detection, prevention, and treatment of diseases, particularly cancer.
EYPT vs PRE — Head-to-Head
Income Statement — Q4 2025 vs Q3 2023
| Metric | | |
|---|---|---|
| Revenue | $619.0K | $4.3M |
| Net Profit | $-67.6M | — |
| Gross Margin | — | 44.9% |
| Operating Margin | -11364.3% | -396.2% |
| Net Margin | -10922.3% | — |
| Revenue YoY | -94.7% | — |
| Net Profit YoY | -63.3% | — |
| EPS (diluted) | $-0.82 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $619.0K | — | ||
| Q3 25 | $966.0K | — | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $24.5M | — | ||
| Q4 24 | $11.6M | — | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $9.5M | — | ||
| Q1 24 | $11.7M | — |
| Q4 25 | $-67.6M | — | ||
| Q3 25 | $-59.7M | — | ||
| Q2 25 | $-59.4M | — | ||
| Q1 25 | $-45.2M | — | ||
| Q4 24 | $-41.4M | — | ||
| Q3 24 | $-29.4M | — | ||
| Q2 24 | $-30.8M | — | ||
| Q1 24 | $-29.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 93.0% | — | ||
| Q2 24 | 85.2% | — | ||
| Q1 24 | 93.5% | — |
| Q4 25 | -11364.3% | — | ||
| Q3 25 | -6420.8% | — | ||
| Q2 25 | -1166.8% | — | ||
| Q1 25 | -199.7% | — | ||
| Q4 24 | -390.4% | — | ||
| Q3 24 | -311.2% | — | ||
| Q2 24 | -364.5% | — | ||
| Q1 24 | -285.2% | — |
| Q4 25 | -10922.3% | — | ||
| Q3 25 | -6183.4% | — | ||
| Q2 25 | -1114.3% | — | ||
| Q1 25 | -184.8% | — | ||
| Q4 24 | -357.3% | — | ||
| Q3 24 | -279.0% | — | ||
| Q2 24 | -325.3% | — | ||
| Q1 24 | -250.6% | — |
| Q4 25 | $-0.82 | — | ||
| Q3 25 | $-0.85 | — | ||
| Q2 25 | $-0.85 | — | ||
| Q1 25 | $-0.65 | — | ||
| Q4 24 | $-0.65 | — | ||
| Q3 24 | $-0.54 | — | ||
| Q2 24 | $-0.58 | — | ||
| Q1 24 | $-0.55 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $306.1M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $306.1M | — |
| Total Assets | $364.0M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $306.1M | — | ||
| Q3 25 | $204.0M | — | ||
| Q2 25 | $255.7M | — | ||
| Q1 25 | $318.2M | — | ||
| Q4 24 | $370.9M | — | ||
| Q3 24 | $253.8M | — | ||
| Q2 24 | $280.2M | — | ||
| Q1 24 | $299.3M | — |
| Q4 25 | $306.1M | — | ||
| Q3 25 | $200.2M | — | ||
| Q2 25 | $246.0M | — | ||
| Q1 25 | $298.4M | — | ||
| Q4 24 | $336.5M | — | ||
| Q3 24 | $218.7M | — | ||
| Q2 24 | $228.3M | — | ||
| Q1 24 | $249.9M | — |
| Q4 25 | $364.0M | — | ||
| Q3 25 | $251.7M | — | ||
| Q2 25 | $301.1M | — | ||
| Q1 25 | $362.6M | — | ||
| Q4 24 | $418.5M | — | ||
| Q3 24 | $300.9M | — | ||
| Q2 24 | $324.2M | — | ||
| Q1 24 | $329.2M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-65.0M | — |
| Free Cash FlowOCF − Capex | $-66.0M | — |
| FCF MarginFCF / Revenue | -10667.7% | — |
| Capex IntensityCapex / Revenue | 159.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-243.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-65.0M | — | ||
| Q3 25 | $-59.4M | — | ||
| Q2 25 | $-62.6M | — | ||
| Q1 25 | $-53.1M | — | ||
| Q4 24 | $-35.8M | — | ||
| Q3 24 | $-39.0M | — | ||
| Q2 24 | $-20.2M | — | ||
| Q1 24 | $-31.2M | — |
| Q4 25 | $-66.0M | — | ||
| Q3 25 | $-60.2M | — | ||
| Q2 25 | $-63.8M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $-36.2M | — | ||
| Q3 24 | $-40.6M | — | ||
| Q2 24 | $-21.1M | — | ||
| Q1 24 | $-32.4M | — |
| Q4 25 | -10667.7% | — | ||
| Q3 25 | -6226.9% | — | ||
| Q2 25 | -1196.5% | — | ||
| Q1 25 | -218.4% | — | ||
| Q4 24 | -312.7% | — | ||
| Q3 24 | -385.8% | — | ||
| Q2 24 | -222.4% | — | ||
| Q1 24 | -277.0% | — |
| Q4 25 | 159.3% | — | ||
| Q3 25 | 82.6% | — | ||
| Q2 25 | 22.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 15.0% | — | ||
| Q2 24 | 9.5% | — | ||
| Q1 24 | 10.2% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
